Jigar Raythatha has spent nearly 20 years in the biotechnology industry in a variety of business functions. He rejoined Constellation in May 2017 from Jounce Therapeutics, where he held the role of chief business officer. He was the first employee at Jounce and helped build the company from its inception to a 100-person, publicly traded research and development organization. Previously, he served as head of corporate development at Constellation, where he led business development, strategy and program and alliance management functions. Prior to Constellation, Mr. Raythatha worked with Red Abbey Venture Partners, initially as a Kauffman fellow, later as a principal and finally a venture partner. Earlier in his career, Mr. Raythatha held roles of increasing responsibility at Biogen and A.T. Kearney. He earned a Master of Business Administration from Columbia University and a Bachelor of Arts in biochemistry and economics from Rutgers University.
Dr. Jim Audia joined Constellation in January 2011 following a highly productive career in drug discovery at Eli Lilly and Company. Dr. Audia held several key leadership roles during his 23-year tenure at Lilly. As a Distinguished Lilly Scholar, the highest level of the company’s scientific ladder, he made seminal technical and strategic contributions to the Lilly drug pipeline. Prior to this role, Dr. Audia was Executive Director, Discovery Chemistry Research and Technologies, where he had global responsibility for delivery of small molecule drug candidates across all therapeutic areas. He also played a major role in companywide leadership of product strategy and portfolio management for Lilly for more than a decade. Over the course of his career, Dr. Audia’s scientific work has contributed to more than 12 development candidates, including transformative contributions to the treatment of Alzheimer’s disease through his discovery of both the first gamma secretase inhibitor and an industry-leading beta secretase inhibitor. Dr. Audia is a named inventor on more than 90 issued US patents and has published and presented extensively. He received his Ph.D. in Organic Chemistry from the University of South Carolina and did postdoctoral training at Yale University before joining Lilly.
Ms. Brenda Sousa joined Constellation as Vice President of Human Resources for Constellation in March 2010. Prior to joining Constellation Ms. Sousa was the Vice President of Human Resources and Operations at EPIX Pharmaceuticals, where she served as a member of the global executive management team and focused on the development and implementation of business strategy, operations, and organizational development for US companies with international offices. Before joining EPIX, she was Director of Human Resources for RKS Health Ventures and Spence Center for Women’s Health, a start-up venture that was ultimately purchased by Partners Healthcare. Prior to her human resources career, Ms. Sousa worked in the hospitality industry focusing on sales and marketing. Brenda joined the Board of Career Collaborative in 2004 where she initiated and served as Chair of the Employer Advisory Board. Brenda holds a Bachelor of Arts Degree from the University of Massachusetts.
Mr. Jaffe joined Constellation in April 2012 bringing over 12 years of experience in corporate finance and strategic management to his role. Previously, Mr. Jaffe served as CFO and VP of Business Development at Zafgen, a Third Rock Ventures’ portfolio company. He has also held senior positions in a number of private, venture-backed companies in the life science and cleantech space, including Alantos Pharmaceuticals, which under the leadership of Dr. Dionne, was acquired by Amgen in 2007. Prior to Alantos, Mr. Jaffe was a principal at Earlybird Venture Capital (Munich, Germany), where he supported new investments activities and existing portfolio companies. He also worked at the Boston Consulting Group, where he was a member of the pharmaceutical practice group, assisting Fortune 500 companies with strategic management issues. Mr. Jaffe holds a M.S. in molecular biology from the Massachusetts Institute of Technology, an MBA from INSEAD (Fontainebleau, France).
A board-certified medical oncologist by training, Dr. Adrian Senderowicz brings to Constellation more than two decades of experience in the life sciences. As the principal investigator for a multitude of clinical trials in solid and hematological tumors, Dr. Senderowicz has significant regulatory expertise as a former clinical team leader at the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) Division of Drug Oncology Products. Prior to joining Constellation, Dr. Senderowicz served as chief medical officer at Cerulean Pharma, where he helped secure fast-track designation for the company’s lead clinical development program in two indications. Previously, Dr. Senderowicz held roles of increasing responsibility at Ignyta, Inc., Sanofi Oncology, Tokai Pharmaceuticals and AstraZeneca plc. He began his career as an investigator at the National Cancer Institute before joining the FDA’s CDER.
Dr. Sims joined Constellation Pharmaceuticals in 2008 as a founding scientist. With nearly 20 years of experience in chromatin biology and transcription, Dr. Sims helped establish Constellation’s industry-leading epigenetics platform. Dr. Sims led the discovery and translational efforts for CPI-0610, a novel BET bromodomain inhibitor currently in phase 1 clinical development for hematologic malignancies. His team’s notable work, along with others in the field, includes the discovery that BET bromodomain inhibition silences the expression of the MYC oncogene. Dr. Sims has authored more than 30 scientific publications in top-tier journals, including Science, Nature, and Cell. He received his Ph.D. in Cellular and Molecular Biology from the University of Texas at Austin and completed his postdoctoral training at UMDNJ-Robert Wood Johnson Medical School and the New York University School of Medicine.
Dr. Trojer was involved in the foundation of Constellation in early 2008 and joined the Company as a founding scientist. He has held multiple positions of increasing responsibility at Constellation. Among his many achievements, Dr. Trojer drove Constellation’s EZH2 program leading to the clinical launch of CPI-1205 currently in Ph 1 clinical trials for Lymphoma. Dr. Trojer is internationally recognized for his expertise in chromatin biology and its control of gene transcription. Dr. Trojer has authored dozens of scientific publications and is a frequent lecturer in the epigenetics space. He completed his postdoctoral studies at NYU Medical School in Dr. Danny Reinberg’s laboratory, prior to which he received both a Ph.D. in protein biochemistry and molecular biology and M.S. in microbiology from the Leopold Franzens University in Innsbruck, Austria.